CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,344,017 | -22.7% | 198,993 | +12.6% | 0.03% | -18.8% |
| Q2 2023 | $5,617,452 | +9.6% | 176,705 | -15.9% | 0.03% | -8.6% |
| Q1 2023 | $5,126,412 | -31.9% | 210,185 | -11.9% | 0.04% | -44.4% |
| Q4 2022 | $7,527,179 | +76.1% | 238,655 | +57.8% | 0.06% | +40.0% |
| Q3 2022 | $4,274,000 | +118.5% | 151,242 | +104.4% | 0.04% | +150.0% |
| Q2 2022 | $1,956,000 | -50.6% | 73,978 | -34.5% | 0.02% | -21.7% |
| Q1 2022 | $3,956,000 | -9.7% | 112,999 | -16.4% | 0.02% | 0.0% |
| Q4 2021 | $4,383,000 | +81.4% | 135,197 | +65.1% | 0.02% | +35.3% |
| Q3 2021 | $2,416,000 | +125.4% | 81,894 | +95.8% | 0.02% | +142.9% |
| Q2 2021 | $1,072,000 | +26.7% | 41,835 | -32.1% | 0.01% | +16.7% |
| Q1 2021 | $846,000 | – | 61,585 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |